Pfizer Inc. filed an 8-K on November 3, 2026, disclosing that its Board of Directors unanimously elected Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026.

Key Highlights

  • Permanent appointment: Cecile Guegan was elected CFO and Executive Vice President by unanimous Board vote, effective November 1, 2026.
  • Prior interim role: Guegan, age 55, had served as Interim Chief Financial Officer since August 16, 2026, as previously reported in a June 18, 2026 filing.
  • Base salary: The Compensation Committee approved an annual base salary of $1,300,000 for Guegan as of the effective date.
  • Annual cash incentive: Guegan received an annual target cash incentive opportunity of $1,300,000, representing 100% of her annual base salary, to be determined based on salary paid during the year.
  • Industry tenure: According to the filing, Guegan has more than 25 years of global finance leadership in the pharmaceutical industry.
  • Pfizer history: She joined Pfizer in connection with its 2009 acquisition of Wyeth and has held successive finance leadership roles across Oncology, Research and Development, and the Global Biopharmaceuticals Group.

Pfizer Board Confirms Guegan as CFO Following Interim Period

Pfizer Inc. (NYSE:PFE) disclosed in a current report dated October 30, 2026, and filed November 3, 2026, that its Board of Directors unanimously elected Cecile Guegan to serve permanently as Chief Financial Officer and Executive Vice President. The appointment became effective November 1, 2026. The filing noted that Guegan, 55, had previously been appointed Interim Chief Financial Officer effective August 16, 2026, as disclosed in a Form 8-K filed with the SEC on June 18, 2026.

According to the filing, Guegan joined Pfizer through its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses. At Pfizer, she most recently served as Senior Vice President of Finance for the Global Biopharmaceuticals business since 2022, and as Vice President, Finance, Research and Development and Business Office from 2020 to 2022. The filing states she holds a master's degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting (French DECF).

The Compensation Committee of the Board unanimously approved Guegan's compensation arrangements as of the effective date. These include an annual base salary of $1,300,000 and an annual target cash incentive opportunity of $1,300,000, which the filing describes as representing 100% of her annual base salary, to be determined based on the salary paid during the year. A press release dated November 3, 2026, was attached as Exhibit 99.1 to the filing.

What Was Disclosed

Pfizer's 8-K disclosed the Board's unanimous election of Cecile Guegan as permanent CFO and Executive Vice President effective November 1, 2026, along with her approved compensation, including a $1,300,000 base salary and a $1,300,000 annual target cash incentive.